Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary

Immix Biopharma

07/08/2026 22:46

Immix Biopharma, Inc. IMMX.OQ reported a quarterly adjusted loss of 18 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -22 cents.  The mean expectation of seven analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -22 cents to -15 cents per share.
Reported revenue was zero​; analysts expected zero. 
Immix Biopharma, Inc.'s reported EPS for the quarter was a loss of 18 cents​.
The company reported a quarterly loss of $11.56 million.
Immix Biopharma, Inc. shares had fallen by 2.4% this quarter and gained 92.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 15.4% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Immix Biopharma, Inc. is $20.00, about 49.7% above its last closing price of $10.06
This summary was machine generated from LSEG data August 7 at 09:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.18
-0.18
Met
Mar. 31 2026 
-0.21
-0.18
Beat
Dec. 31 2025 
-0.16
-0.28
Missed
Sep. 30 2025 
-0.19
-0.24
Missed